Navigating complex manufacturing for highly potent oral solid doses
Highly potent oral solid dosage (HPOSD) products present unique manufacturing and regulatory challenges. As the number of highly potent APIs in development continues to grow, pharmaceutical companies must carefully consider containment strategies, facility infrastructure, and quality systems to support safe and compliant production.
In this whitepaper, “Making the complex simple for highly potent oral solid dosage forms,” explore key considerations for navigating the regulatory and operational complexities associated with HPOSD manufacturing.
Download the whitepaper to explore:
- How highly potent APIs are defined and why they require specialized manufacturing approaches
- Key safety considerations for operators, products, and manufacturing environments
- Evolving regulatory models shaping HPOSD production and compliance expectations
- Infrastructure and containment strategies used to help minimize cross-contamination risks
- Operational considerations when selecting a contract manufacturing organization for HPOSD programs
Powered by Pfizer expertise, Pfizer CentreOne provides specialized facilities and manufacturing capabilities designed to support highly potent oral solid dose products across global markets.
Download the whitepaper to explore insights that can help inform your HPOSD manufacturing strategy.
Pfizer CentreOne
Free Download
Fill out the form
